Trials / Completed
CompletedNCT01199068
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with erlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-7017 | CS-7017 from 0.25 mg to 0.50 mg twice daily |
| DRUG | Erlotinib | Erlotinib 150 mg once daily |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2010-09-10
- Last updated
- 2021-05-13
- Results posted
- 2020-07-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01199068. Inclusion in this directory is not an endorsement.